1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Drugs In Development, 2022, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Organophosphate and Carbamate Poisoning - Overview
- Organophosphate and Carbamate Poisoning - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Organophosphate and Carbamate Poisoning - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
- AntoXa Corp
- Countervail Corp
- PlantVax Inc
- Shanghai Leado Pharmaceutical Technology Co Ltd
- Organophosphate and Carbamate Poisoning - Drug Profiles
- AM-132 - Drug Profile
- Product Description
- Mechanism Of Action
- galantamine hydrobromide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LD-04001 - Drug Profile
- Product Description
- Mechanism Of Action
- PlantVax-1502-HN - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RS-194B - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- Organophosphate and Carbamate Poisoning - Dormant Projects
- Organophosphate and Carbamate Poisoning - Discontinued Products
- Organophosphate and Carbamate Poisoning - Product Development Milestones
- Featured News & Press Releases
- Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Organophosphate and Carbamate Poisoning, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Organophosphate and Carbamate Poisoning - Pipeline by AntoXa Corp, 2022
- Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, 2022
- Organophosphate and Carbamate Poisoning - Pipeline by PlantVax Inc, 2022
- Organophosphate and Carbamate Poisoning - Pipeline by Shanghai Leado Pharmaceutical Technology Co Ltd, 2022
- Organophosphate and Carbamate Poisoning - Dormant Projects, 2022
- Organophosphate and Carbamate Poisoning - Discontinued Products, 2022
- Number of Products under Development for Organophosphate and Carbamate Poisoning, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AntoXa Corp
- Countervail Corp
- PlantVax Inc
- Shanghai Leado Pharmaceutical Technology Co Ltd
